Industry and Geographic Information (Tables)

12 Months Ended

Dec. 31, 2016

Segment Reporting [Abstract]

Sales to Individual Customers in Excess of 10% of Total Revenue

The Company had sales to individual customers in excess of 10% of total revenue, as follows:

	Year ended December 31,
	2016		2015		2014
Customer:
A	16	%	20	%	19	%
B	15	%	17	%	18	%
C	13	%	11	%	11	%
	44	%	48	%	48	%

Long-Lived Assets (Excluding Intangible Assets) and Total Net Revenue

The following presents long-lived assets (excluding intangible assets) and total net revenue by geographic territory (in thousands):

	Long-lived assets as of December 31,				Total revenue  for the years ended December 31,
	2016		2015		2016		2015		2014
Domestic	$	50,774	$	52,426	$	158,244	$	168,809	$	159,845
Foreign	84		121		33,359		27,320		24,313
	$	50,858	$	52,547	$	191,603	$	196,129	$	184,158

Consolidated Net Product Revenues by Disease State

Consolidated net revenues by product category are as follows (in thousands):

	Year ended December 31,
	2016		2015		2014
Immunoassays	$	121,416	$	130,348	$	118,715
Molecular	9,506		5,424		3,418
Virology	40,083		43,747		44,771
Specialty products	9,387		9,001		7,779
Royalties, grants and other	11,211		7,609		9,475
	$	191,603	$	196,129	$	184,158